Search Result

Results for "

tubules

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Angiotensin Receptor (4) Antibiotic (1) Bacterial (1) Biochemical Assay Reagents (3) Carbonic Anhydrase (2) Chloride Channel (2) Dopamine Receptor (1) Drug Derivative (1) Drug Metabolite (2) Endogenous Metabolite (3) Ferroptosis (1) FGFR (2) GLUT (1) iGluR (1) Isotope-Labeled Compounds (2) Keap1-Nrf2 (1) Lipoxygenase (1) Microtubule/Tubulin (1) NKCC (4) Parasite (1) Potassium Channel (1) Reference Standards (4) ROS Kinase (1) Sodium Channel (2) Vasopressin Receptor (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (10) Endocrinology (3) Infection (2) Inflammation/Immunology (2) Metabolic Disease (11) Neurological Disease (2)

By Targets:

5-HT Receptor (1)

Angiotensin Receptor (4)

Antibiotic (1)

Bacterial (1)

Biochemical Assay Reagents (3)

Carbonic Anhydrase (2)

Chloride Channel (2)

Dopamine Receptor (1)

Drug Derivative (1)

Drug Metabolite (2)

Endogenous Metabolite (3)

Ferroptosis (1)

FGFR (2)

GLUT (1)

iGluR (1)

Isotope-Labeled Compounds (2)

Keap1-Nrf2 (1)

Lipoxygenase (1)

Microtubule/Tubulin (1)

NKCC (4)

Parasite (1)

Potassium Channel (1)

Reference Standards (4)

ROS Kinase (1)

Sodium Channel (2)

Vasopressin Receptor (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (10)

Endocrinology (3)

Infection (2)

Inflammation/Immunology (2)

Metabolic Disease (11)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-118607

VU041	Potassium Channel Parasite	Infection
VU041 is a first submicromolar-affinity inhibitor of *Anopheles (An.) gambiae* and Aedes (Ae.) aegypti inward rectifier potassium 1 (Kir1) channels with IC₅₀ values of 2.5 μM and 1.7 μM, respectively. VU041 inhibits appreciably is mammalian Kir2.1 (IC₅₀ of 12.7 μM), and has less inhibitory effect on mammalian Kir1.1, Kir4.1, Kir6.2/SUR1, and Kir7.1. VU041 also induces impaired Malpighian tubule function .

HY-21197

Perfluoroenanthic acid Perfluoroheptanoic acid; Tridecafluoroheptanoic acid; PFHpA	iGluR	Neurological Disease
Perfluoroenanthic acid (Perfluoroheptanoic acid) is a type of perfluoroalkyl substance (PFAS) that can negatively impact the development of seminiferous tubules and m6A RNA methylation in the testes of offspring mice when exposed during pregnancy, consequently disrupting spermatogenesis and leading to reproductive toxicity. Perfluoroenanthic acid alters the morphology of dendritic spines and synaptic formation in primary cortical neuron cultures, enhancing neuronal activity and synaptic transmission, and increasing the expression of excitatory synapse-related proteins Synaptophysin and PSD95 .

HY-B1127

Betamipron N-Benzoyl-β-alanine	Bacterial Antibiotic	Others
Betamipron is a chemical compound which is used together with Panipenem to inhibit Panipenem uptake into the renal tubule and prevent nephrotoxicity.

HY-B0908

Meticrane 2 Publications Verification	Sodium Channel Chloride Channel	Cardiovascular Disease
Meticrane is a diuretic. Meticrane inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension.

HY-125062

Steviolmonoside Glucosilsteviol	GLUT	Metabolic Disease
Steviolmonoside (Glucosilsteviol) is a structural analogue of steviol. Steviolmonoside decreases glucose production and inhibits oxygen uptake in rat renal cortical tubules .

HY-109542

Cyclopenthiazide	Biochemical Assay Reagents	Metabolic Disease
Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney .

HY-P2766A

Trehalase, Microorganism	Biochemical Assay Reagents	Metabolic Disease
Trehalase, Microorganism (EC 3.2.1.28) is a trehalase that can effectively degrade trehalose in some bacteria. Trehalase, Microorganism can be used as a marker for acute kidney injury caused by proximal tubule damage .

HY-W687496

Methyl retinoate Vitamin A acid methyl ester	Drug Derivative	Others
Methyl retinoate (Vitamin A acid methyl ester) is a derivative of vitamin A. Methyl retinoate causes degenerative changes in the seminiferous tubules in Sprague Dawley rats .

HY-137364

Disulfamide	Carbonic Anhydrase	Cardiovascular Disease Metabolic Disease
Disulfamide, an orally active diuretic, is a carbonic anhydrase inhibitor with the IC₅₀ value of 0.07 μM. Disulfamide leads to diuresis by inhibiting carbonic anhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal tubule .

HY-B0908R

Meticrane (Standard)	Reference Standards Sodium Channel Chloride Channel	Cardiovascular Disease
Meticrane (Standard) is the analytical standard of Meticrane. This product is intended for research and analytical applications. Meticrane is a diuretic. Meticrane inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension.

HY-131511

Rovicurt Permethrin-tetramethrin mixture	Endogenous Metabolite	Others
Rovicurt (Permethrin-tetramethrin mixture) is a pesticide that has the activity of stimulating biological adaptation mechanisms. Rovicurt increases the diameter of seminiferous tubules and the number of Sertoli cells. Rovicurt also improves the fertilizing ability of sperm .

HY-107131

ALM-201	Microtubule/Tubulin	Cancer
ALM-201 is a peptide inhibitor of angiogenesis targeting microtubule. ALM-201 can inhibit cells migration, tubule formation and microvessel formation. ALM-201 can be used for the research of cancer .

HY-P3695

VSPPLTLGQLLS	FGFR	Cancer
VSPPLTLGQLLS is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .

HY-109542R

Cyclopenthiazide (Standard)	Biochemical Assay Reagents Reference Standards	Metabolic Disease
Cyclopenthiazide (Standard) is the analytical standard of Cyclopenthiazide. This product is intended for research and analytical applications. Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney .

HY-P3695A

VSPPLTLGQLLS TFA	FGFR	Cancer
VSPPLTLGQLLS TFA is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS TFA inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .

HY-167735

Salvizol Bisdequalinium diacetate	Others	Infection
Salvizol (Bisdequalinium diacetate) is a chemotherapeutic agent with a broad spectrum of bactericidal activity, effective in the apical third of root canals. Salvizol possesses the ability to dissolve organic dentin matrix, facilitating mineralization and tubule exposure. Salvizol maintains a neutral pH, ensuring biological compatibility while exhibiting significant cleansing potency.

HY-B1363

Bendroflumethiazide Bendrofluazide	NKCC	Cardiovascular Disease
Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .

HY-119086

L-651392	Lipoxygenase	Inflammation/Immunology
L-651392 is an orally active and specific 5-lipoxygenase inhibitor that inhibits the production of leukotrienes. L-651392 controls the inflammatory process in Escherichia coli pyelonephritis by preventing inflammatory cells from reaching the site of infection and protecting the renal tubules from inflammation-related damage during pyelonephritis .

HY-165423

DM-4111	Vasopressin Receptor Drug Metabolite	Cardiovascular Disease
DM-4111, one of the major monohydroxyl metabolites of Tolvaptan (HY-17000), is a potent vasopressin V₂ receptor inhibitor. DM-4111 inhibits water reabsorption in the renal tubules, thereby promoting the excretion of electrolyte-free water. DM-4111 is promising for research of cardiovascular diseases .

HY-P1792

Angiotensin II (1-4), human	Angiotensin Receptor	Metabolic Disease Endocrinology
Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca ²⁺ levels. Angiotensin II also acts at the Na ⁺/H ⁺ exchanger in the proximal tubules of the kidney .

HY-P1792A

Angiotensin II (1-4), human TFA	Angiotensin Receptor	Metabolic Disease Endocrinology
Angiotensin II (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca ²⁺ levels. Angiotensin II also acts at the Na ⁺/H ⁺ exchanger in the proximal tubules of the kidney .

HY-P1769

Angiotensin II (5-8), human	Angiotensin Receptor	Metabolic Disease Endocrinology
Angiotensin II (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensin II . Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca ²⁺ levels. Angiotensin II also acts at the Na ⁺/H ⁺ exchanger in the proximal tubules of the kidney .

HY-N13214

Maca Extract (10:1)	Others	Metabolic Disease
Maca Extract is a maca extract. Maca Extract has the potential to improve fertility and sexual function, and can improve non-obstructive azoospermia. The polysaccharide part is its active ingredient. Maca Extract can alleviate seminiferous tubule vacuolation and testicular lesions. It improves sperm quantity and quality by promoting the recovery of seminiferous epithelium, inhibiting stromal cell proliferation, and increasing serum testosterone levels. .

HY-B1363S

Bendroflumethiazide-d5 Bendrofluazide-d₅	Isotope-Labeled Compounds NKCC	Cardiovascular Disease
Bendroflumethiazide-d₅ (Bendrofluazide-d₅) is the deuterium labeled Bendroflumethiazide (HY-B1363).Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .

HY-B1363R

Bendroflumethiazide (Standard) Bendrofluazide (Standard)	NKCC Reference Standards	Cardiovascular Disease
Bendroflumethiazide (Standard) (Bendrofluazide (Standard)) is the analytical standard of Bendroflumethiazide (HY-B1363). This product is intended for research and analytical applications. Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .

HY-B1363S1

Bendroflumethiazide-d7 Bendrofluazide-d₇	Isotope-Labeled Compounds NKCC	Cardiovascular Disease
Bendroflumethiazide-d₇ (Bendrofluazide-d₇) is deuterium labeled Bendroflumethiazide (HY-B1363). Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .

HY-113724

S-8666	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
S-8666 is an orally active uricosuric antihypertensive diuretic. The S-8666 has both S-(-)- and R-(+)-isomers. The diuretic and sodium-excretion activities of it are entirely dominated by the S-(-)-isomer, while the R-(+)-isomer shows no significant activity. S-8666 relies on the organic acid transport system to be secreted through the proximal tubule. S-8666 exhibits a clear uric acid excretion-promoting activity and diuretic effect in various species (such as rats and chimpanzees) .

HY-134043

Chlorthalidone Impurity G Chlorthalidone EP Impurity G	Carbonic Anhydrase	Cardiovascular Disease
Chlorthalidone Impurity G (Chlorthalidone EP Impurity G) is a potential impurity found in commercial preparations of chlorthalidone with moderate antihypertensive effects. Chlorthalidone is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal tubule of the kidney, thereby preventing sodium and chloride reabsorption, resulting in decreased plasma volume and cardiac output. It also inhibits carbonic anhydrase (CA), including isoenzymes CAVB, VII, IX, XII, and XIII (Kis=2.8-23 nM) and to a lesser extent CAI, CAII, IV, VA, and VI (Ki=138-1,347 nM), mediating vasodilatory activity.

HY-100057

BMY 28674 6-Hydroxybuspirone; 6'-Hydroxybuspirone; BMS 528215	5-HT Receptor Drug Metabolite Dopamine Receptor	Neurological Disease
BMY 28674 (6-Hydroxybuspirone) is the active metabolite of the anxiolytic buspirone (HY-B1115A) and is metabolized by CYP3A4.4. BMY 28674 binds to the serotonin (5-HT) receptor subtype 5-HT1A in the rat hippocampus and dorsal raphe (EC₅₀s are 4 and 1 μM, respectively) and is an antagonist of dopamine D2, D3, and D4 receptors (IC₅₀s are 3.1, 4.9, and 0.85 μM, respectively). BMY 28674 also inhibits organic cation transporter 1 (OCT1), OCT2, and OCT3 expressing human transporters in S2 proximal tubule cells in a concentration-dependent manner.

HY-N0394R

L-Cystine (Standard)	Reference Standards Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2	Metabolic Disease Inflammation/Immunology Cancer
L-Cystine (Standard) is the analytical standard of L-Cystine. This product is intended for research and analytical applications. L-Cystine, the extracellular form of L-Cysteine (HY-Y0337), is a nutritionally dispensable semiessential sulfur-containing amino acid, occurring in proteins of plants and animals. L-Cystine induces Nrf2 protein elevation in a Keap1 (HY-P75897)-dependent manner and activates Nrf2 transcription factor. L-cystine can elicit cytoprotection by reducing ROS generation and protecting against oxidant- or doxorubicin-induced apoptosis. The reduced reabsorption of L-Cystine in renal tubules and its poor solubility in urine are the important causes of cystine precipitation and cystine crystal formation eventually leading to kidney stones. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and cystinosis

HY-102093A

ZD 7155	Angiotensin Receptor	Others
ZD 7155 is an AT1R selective antagonist with renal function modulating activity. The effects of ZD 7155 on glomeruli and tubules were measured in 1- (N = 9) and 6-week-old (N = 13) lambs. Pretreatment with ZD 7155 after L-NAME infusion did not alter glomerular function in 1- or 6-week-old lambs. During postnatal development, Ang II modulates the effects of NO on electrolyte handling via AT1R and AT2R. In 6-week-old lambs, selective inhibition of AT1R and AT2R increased the excretion of Na+, K+, and Cl-. In 6-week-old lambs, pretreatment with ZD 7155 and PD 123319 followed by the addition of L-NAME increased urine flow rate by 200%, free water clearance by 50%, and decreased urine osmolality by 40%. The same trends of changes in these variables were also observed when L-NAME was added to ZD 7155 or PD 123319, although to a lesser extent.

Cat. No.	Product Name

HY-L060

Cytoskeleton Compound Library	1,859 compounds
The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases. MCE designs a unique collection of 1,859 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

Cytoskeleton Compound Library

1,859 compounds

The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases.

MCE designs a unique collection of 1,859 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P3695

VSPPLTLGQLLS	FGFR	Cancer
VSPPLTLGQLLS is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .

HY-P1769

Angiotensin II (5-8), human	Angiotensin Receptor	Metabolic Disease Endocrinology
Angiotensin II (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensin II . Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca ²⁺ levels. Angiotensin II also acts at the Na ⁺/H ⁺ exchanger in the proximal tubules of the kidney .

HY-P11184

CAP2b	Peptides	Others
CAP2b is a cardioacceleratory peptide that is present in Drosophila. CAP2b stimulates tubule fluid secretion via cGMP-signaling pathway .

HY-107131

ALM-201	Microtubule/Tubulin	Cancer
ALM-201 is a peptide inhibitor of angiogenesis targeting microtubule. ALM-201 can inhibit cells migration, tubule formation and microvessel formation. ALM-201 can be used for the research of cancer .

HY-P3695A

VSPPLTLGQLLS TFA	FGFR	Cancer
VSPPLTLGQLLS TFA is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS TFA inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .

HY-P1792

Angiotensin II (1-4), human	Angiotensin Receptor	Metabolic Disease Endocrinology
Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca ²⁺ levels. Angiotensin II also acts at the Na ⁺/H ⁺ exchanger in the proximal tubules of the kidney .

HY-P1792A

Angiotensin II (1-4), human TFA	Angiotensin Receptor	Metabolic Disease Endocrinology
Angiotensin II (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca ²⁺ levels. Angiotensin II also acts at the Na ⁺/H ⁺ exchanger in the proximal tubules of the kidney .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0394R

L-Cystine (Standard)	Human Gut Microbiota Metabolites Microorganisms Source classification Amino acids Endogenous metabolite	Reference Standards Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2
L-Cystine (Standard) is the analytical standard of L-Cystine. This product is intended for research and analytical applications. L-Cystine, the extracellular form of L-Cysteine (HY-Y0337), is a nutritionally dispensable semiessential sulfur-containing amino acid, occurring in proteins of plants and animals. L-Cystine induces Nrf2 protein elevation in a Keap1 (HY-P75897)-dependent manner and activates Nrf2 transcription factor. L-cystine can elicit cytoprotection by reducing ROS generation and protecting against oxidant- or doxorubicin-induced apoptosis. The reduced reabsorption of L-Cystine in renal tubules and its poor solubility in urine are the important causes of cystine precipitation and cystine crystal formation eventually leading to kidney stones. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and cystinosis

Cat. No.	Product Name	Chemical Structure

HY-B1363S

Bendroflumethiazide-d5
Bendroflumethiazide-d₅ (Bendrofluazide-d₅) is the deuterium labeled Bendroflumethiazide (HY-B1363).Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .

Bendroflumethiazide-d5

Bendroflumethiazide-d₅ (Bendrofluazide-d₅) is the deuterium labeled Bendroflumethiazide (HY-B1363).Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .

HY-B1363S1

Bendroflumethiazide-d7
Bendroflumethiazide-d₇ (Bendrofluazide-d₇) is deuterium labeled Bendroflumethiazide (HY-B1363). Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .

Bendroflumethiazide-d7

Bendroflumethiazide-d₇ (Bendrofluazide-d₇) is deuterium labeled Bendroflumethiazide (HY-B1363). Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

tubules

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products